Research

Müller, E.; Enzlein, T.; Niemeyer, D.; von Ammon, L.; Stumpo, K.; Biber, K.; Klein, C.; Hopf, C. Exploring the Aβ Plaque Microenvironment in Alzheimer’s Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer. Pharmaceuticals 2025, 18, 252. https://doi.org/10.3390/ph18020252 Abstract Amyloid-β (Aβ) plaque deposits in the brain are a hallmark of Alzheimer’s disease (AD) neuropathology. Plaques […]

Approval based on positive results from Phase III ATTRibute-CM study / Beyonttra™ is a near-complete (≥90%) stabilizer of transthyretin (TTR) minimizing amyloid formation / Phase III ATTRibute-CM study with Beyonttra™ has shown clear benefits on cardiovascular endpoints already starting as early as 3 months after treatment initiation Berlin, February 11, 2025 – The European Commission has […]

Researchers have increased the resolution in fluorescence microscopy by a factor of 30 without having to sequentially switch fluorescent molecules between light and dark states. The Nobel Prize-winning STED and PALM/STORM microscopes, as well as other super-resolution fluorescence microscopes, provide resolutions of a fraction of the wavelength of light. However, to image adjacent fluorescent molecules […]

International project consortium is coordinated at Heidelberg University Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. That is the goal of an international research project in which scientists work on new approaches to combating highly dangerous viral diseases such […]

The results from a phase 3 trial involving 662 patients from 67 clinics led by Heidelberg University Hospital and the Heidelberg Medical Faculty at Heidelberg University indicate that a new immunotherapeutic approach keeps the disease under control for longer. The data has just been published in the Journal of Clinical Oncology. The study has been […]

February 19, 2025 Basel, Switzerland, 19 February 2025 – Celonic Group, a “Pure Play” biologics contract development and manufacturing organization (CDMO), announced today the signing of a multi-year commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab for Commercial Supply. Catumaxomab is a first-in-class, trifunctional bispecific monoclonal antibody designed for the intraperitoneal treatment of […]

Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of the stomach, where they block acid production. Researchers at the German Cancer Research Center (DKFZ) made the surprising discovery that zinc-carrying proteins, which are found in all […]

Handelsblatt | 07.02.2025 —Innovation — Deutschlands wichtigste Wette auf die Zukunft Handelsblatt Insight Biotechnologie zählt zu den vielversprechendsten Wirtschaftsfeldern. Die Bundesrepublik zeigt dabei laut einer neuen Studie überraschende Stärken. Experten sehen allerdings Probleme, die dringend gelöst werden müssen. Der deutsche Mikrobiologe Robert Koch findet 1882 den Erreger für die Krankheit Tuberkulose. 1895: Wilhelm Conrad Röntgen entdeckt in […]

BioMed X Institute, in collaboration with the Government of Barbados and the European Commission, is launching BioMed X Barbados, a new research initiative focused on better treatment of cardiometabolic diseases in individuals of African descent. Heidelberg, Germany / Bridgetown, Barbados – February 20, 2025. BioMed X Institute is proud to announce a partnership with the […]